Ceapro Inc.

Equities

CZO

CA1499071076

Biotechnology & Medical Research

Delayed Toronto S.E. Other stock markets 09:30:00 2024-04-29 am EDT			5-day change	1st Jan Change
0.25 ^CAD	-3.85%		+4.17%	+31.58%

Mar. 28	Ceapro Brief: Parties anticipate completing Transaction in Q2 2024, subject to obtaining all required approvals and satisfying all required conditions	MT
Mar. 28	Ceapro Brief: Says Received Final Court Approval for Merger with Aeterna Zentaris	MT

Ceapro Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023

May 25, 2023 at 09:06 am EDT

Ceapro Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was CAD 3.49 million compared to CAD 6.17 million a year ago. Net loss was CAD 0.38505 million compared to net income of CAD 1.81 million a year ago.

Latest news about Ceapro Inc.

Ceapro Brief: Parties anticipate completing Transaction in Q2 2024, subject to obtaining all required approvals and satisfying all required conditions	Mar. 28	MT
Ceapro Brief: Says Received Final Court Approval for Merger with Aeterna Zentaris	Mar. 28	MT
Aeterna Zentaris Reports Q4 Net Loss of US$5.6 Million, Provides DETECT Trial Update	Mar. 27	MT
Aeterna Zentaris Brief: Announcing Completion of Enrollment in Ongoing Pivotal DETECT-Trial for Diagnosis of Childhood-Onset Growth Hormone Deficiency	Mar. 27	MT
Aeterna Zentaris Brief: Reporting Q4 Net Loss of US$5.6 million, or $1.16 loss per common share	Mar. 27	MT
Ceapro Brief: Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR Arrangement Agreement to Approve Merger of Equals to Create a Diversified Biopharmaceutical Co	Feb. 26	MT
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create Diversified Biopharmaceutical Co	Dec. 14	MT
Aeterna Zentaris and Ceapro Brief: Cos Announcing Merger of Equals to Create a Diversified Biopharmaceutical Co	Dec. 14	MT
Ceapro Inc. Announces Dosing of First Patients In Phase 1-2a Study of Avenanthramides	Dec. 13	MT
Ceapro Inc. Announces Commencement of Patient Dosing in its Phase 1-2a Study Evaluating its Product, Avenanthramides, for Potential Applications in Managing Conditions Related to Inflammation	Dec. 13	CI
Ceapro Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 29	CI
Aeterna Zentaris Inc. entered into a definitive agreement to acquire Ceapro Inc. for CAD 20 million in a merger of equals transaction.	Nov. 28	CI
Ceapro Inc. Initiates Phase 1-2a Study Assessing Avenanthramides For Potential Applications in Inflammation Based Diseases	Nov. 27	MT
Ceapro Inc. Initiates Phase 1-2A Study Assessing Its Product Avenanthramides for Potential Applications in Inflammation Based Diseases	Nov. 27	CI
Ceapro Inc. Announces the Signing of A Technical Collaboration with NATEX Prozesstechnologie Gmbh to Accelerate the Scale-Up of Its Proprietary PGX Technology Towards Commercial Level	Nov. 07	CI
Ceapro Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-29	CI
Ceapro Extends International Supply and Distribution Agreement with German Provider of Active Ingredients, Symrise	23-08-25	MT
Ceapro Inc. Extends Exclusive International Supply and Distribution Agreement with Symrise	23-08-25	CI
Ceapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation	23-07-18	MT
Ceapro Inc. Announces Next Phase of Research Collaboration with the Angiogenesis Foundation	23-07-18	CI
Ceapro Inc. Announces Resignation of Glenn Rourke as A Director	23-06-07	CI
Ceapro Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25	CI
Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases	23-05-23	CI
Ceapro on Findings That Oat Derived Beta Glucan and Avenanthramides Promote Wound Healing, Tissue Regeneration	23-05-03	MT
Ceapro Inc. Announces Positive Results from Research Collaboration with the Angiogenesis Foundation Conducted with Researchers At the University of Arizona	23-05-03	CI

Chart Ceapro Inc.

Duration

Period

More charts

Company Profile

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.

Sector

Biotechnology & Medical Research

Calendar

2024-05-15 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CEAPRO INC.	+31.58%	14.87M
IQVIA HOLDINGS INC.	+2.41%	42.75B
LONZA GROUP AG	+47.87%	41.61B
MODERNA, INC.	+12.37%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.47%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-23.67%	18.12B
MEDPACE HOLDINGS, INC.	+30.52%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.56%	11.76B
UNITED THERAPEUTICS CORPORATION	+8.09%	11B

Other Biotechnology & Medical Research